Last reviewed · How we verify
Aclidinium Bromide 200 µg
Aclidinium bromide is a long-acting muscarinic antagonist that blocks M3 receptors in airway smooth muscle to prevent bronchoconstriction and improve airflow.
Aclidinium bromide is a long-acting muscarinic antagonist that blocks M3 receptors in airway smooth muscle to prevent bronchoconstriction and improve airflow. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Aclidinium Bromide 200 µg |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Aclidinium is a quaternary ammonium anticholinergic compound that selectively antagonizes muscarinic M3 receptors on airway smooth muscle and mucus glands. By blocking acetylcholine-mediated bronchoconstriction, it produces sustained bronchodilation and reduces mucus secretion. The drug is formulated as a dry powder inhaler for maintenance treatment of chronic obstructive pulmonary disease (COPD).
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Urinary retention
Key clinical trials
- Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35) (PHASE3)
- Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38) (PHASE3)
- Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aclidinium Bromide 200 µg CI brief — competitive landscape report
- Aclidinium Bromide 200 µg updates RSS · CI watch RSS
- AstraZeneca portfolio CI